Tenecteplase inferior to alteplase for moderate, severe acute ischemic stroke

In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable functional outcomes compared to a higher standard dose of alteplase, according to data published in The Lancet Neurology.
“Alteplase is the only approved thrombolytic drug in patients with acute ischemic stroke, although international guidelines have implemented tenecteplase as an alternative in highly specific subgroups,” Christopher Elnan Kvistad, PhD, of the department of neurology at Haukeland University Hospital in Norway, and colleagues wrote.
As a follow-up to the

In patients with moderate or severe ischemic stroke, a lower dose of IV tenecteplase yielded less favorable functional outcomes compared to a higher standard dose of alteplase, according to data published in The Lancet Neurology.
“Alteplase is the only approved thrombolytic drug in patients with acute ischemic stroke, although international guidelines have implemented tenecteplase as an alternative in highly specific subgroups,” Christopher Elnan Kvistad, PhD, of the department of neurology at Haukeland University Hospital in Norway, and colleagues wrote.
As a follow-up to the